JARDIANCE

Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate

Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate

In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.

In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable.